The Phase III HOPE-B trial (NCT03569891) showed that a single infusion of EtranaDez (etranacogene dezaparvovec) generated a stable and durable increase in mean Factor IX (FIX) activity and hemostatic protection that outperformed prophylactic infusions of FIX intended to temporarily replace or supplement low levels of the blood-clotting factor. According to CSL Behring, EtranaDez produced mean FIX activity of 39.0 IU/dL at six months and 36.9 IU/dL at 18 months post-infusion . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge

The post Bleeding Cut: CSL Behring Plans H1 Filings for Hemophilia B Gene Therapy appeared first on GEN – Genetic Engineering and Biotechnology News.